Biohaven Pharmaceutical Holding CO Ltd. BHVN
We take great care to ensure that the data presented and summarized in this overview for Biohaven Pharmaceutical Holding Co Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BHVN
View all-
Knoll Capital Management, LLC Miami, FL710KShares$34.6 Million17.51% of portfolio
-
Eaton Vance Management Boston, MA35.9KShares$1.75 Million0.01% of portfolio
-
S. Muoio & Co. LLC New York, NY19KShares$923,5663.79% of portfolio
-
Agf Investments LLC Boston, MA11.6KShares$562,5090.16% of portfolio
-
Birchview Capital, LP Burlington, VT7.37KShares$358,3800.34% of portfolio
-
Brevan Howard Capital Management LP St. Helier, Y96.52KShares$317,4090.0% of portfolio
-
Surevest, LLC Los Angeles, CA751Shares$36,5430.03% of portfolio
-
Private Capital Group, LLC151Shares$7,3470.02% of portfolio
-
Wipfli Financial Advisors Llc,124Shares$6,0330.0% of portfolio
-
American Portfolios Advisors Holbrook, NY86Shares$4,1840.0% of portfolio
Latest Institutional Activity in BHVN
Top Purchases
Top Sells
About BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Insider Transactions at BHVN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2022
|
John W Childs |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,000
-100.0%
|
$1,480,000
$148.5 P/Share
|
|
Oct 03
2022
|
John W Childs |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,025,001
-100.0%
|
$447,700,148
$148.5 P/Share
|
|
Oct 03
2022
|
Vlad Coric Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
830,891
-47.14%
|
$122,971,868
$148.5 P/Share
|
|
Oct 03
2022
|
Vlad Coric Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
92,050
-9.97%
|
$13,623,400
$148.5 P/Share
|
|
Oct 03
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,226
-100.0%
|
$2,105,448
$148.5 P/Share
|
|
Oct 03
2022
|
Robert J Hugin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,900
-100.0%
|
$429,200
$148.5 P/Share
|
|
Oct 03
2022
|
Matthew Buten Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,177
-100.0%
|
$914,196
$148.5 P/Share
|
|
Oct 03
2022
|
Kishan Mehta |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,640
-100.0%
|
$1,574,720
$148.5 P/Share
|
|
Oct 03
2022
|
John Tilton Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,614
-100.0%
|
$238,872
$148.5 P/Share
|
|
Oct 03
2022
|
John Tilton Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,068
-75.85%
|
$750,064
$148.5 P/Share
|
|
Oct 03
2022
|
James Engelhart Strategic Advisor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,900
-100.0%
|
$2,353,200
$148.5 P/Share
|
|
Oct 03
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,292
-100.0%
|
$635,216
$148.5 P/Share
|
|
Oct 03
2022
|
Elyse Stock Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,374
-100.0%
|
$795,352
$148.5 P/Share
|
|
Oct 03
2022
|
Elyse Stock Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,090
-100.0%
|
$1,641,320
$148.5 P/Share
|
|
Oct 03
2022
|
Charles Conway Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,362
-100.0%
|
$3,309,576
$148.5 P/Share
|
|
Oct 03
2022
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,653
-100.0%
|
$1,724,644
$148.5 P/Share
|
|
Oct 03
2022
|
Gregory Bailey |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,583,658
-100.0%
|
$382,381,384
$148.5 P/Share
|
|
Aug 19
2022
|
Gregory Bailey |
BUY
Open market or private purchase
|
Direct |
38,000
+1.45%
|
$5,624,000
$148.04 P/Share
|
|
May 10
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,200
-50.82%
|
$592,200
$141.5 P/Share
|
|
May 10
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+21.4%
|
$119,250
$53.76 P/Share
|